West Pharmaceutical Services Income Statement (2009-2026) | WST

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	723.60M	706.50M	730.80M	720.00M	771.30M	686.90M	708.70M	716.60M	753.80M	747.40M	732.00M	695.40M	702.10M	746.90M	748.80M	698.00M	766.50M	804.60M	805.00M	844.90M
Cost of Revenue (Quarter)	408.50M	418.30M	430.20M	435.40M	449.80M	418.90M	446.60M	445.30M	462.40M	459.10M	453.80M	465.20M	472.10M	482.20M	475.20M	466.10M	492.60M	510.30M	501.10M	548.50M
Gross Profit (Quarter)	315.10M	288.20M	300.60M	284.60M	321.50M	268.00M	262.10M	271.30M	291.40M	288.30M	278.20M	230.20M	230.00M	264.70M	273.60M	231.90M	273.90M	294.30M	303.90M	296.40M
Operating items
Research & Development (Quarter)	13.80M	13.10M	13.70M	14.60M	14.40M	13.60M	15.90M	17.10M	16.50M	16.40M	18.40M	17.60M	17.50M	15.50M	18.50M	16.30M	19.10M	17.10M	21.80M	15.80M
Selling, General & Administrative (Quarter)	92.70M	91.90M	98.00M	83.40M	81.50M	66.30M	85.70M	86.00M	88.40M	89.00M	90.00M	86.70M	83.00M	83.50M	85.30M	88.00M	95.90M	102.70M	107.00M	99.50M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)	106.50M	105.00M	111.70M	98.00M	95.90M	79.90M	101.60M	103.10M	104.90M	105.40M	108.40M	104.30M	100.50M	99.00M	103.80M	104.30M	115.00M	119.80M	128.80M	115.30M
Operating Income (Quarter)	211.30M	181.40M	184.00M	189.70M	228.40M	186.20M	129.70M	155.30M	182.50M	177.30M	160.90M	122.80M	126.20M	161.30M	159.60M	107.00M	153.70M	167.60M	156.60M	177.10M
EBIT (Quarter)	211.30M	181.40M	184.00M	189.70M	228.40M	186.20M	129.70M	155.30M	182.50M	177.30M	160.90M	122.80M	126.20M	161.30M	159.60M	107.00M	153.70M	167.60M	156.60M	177.10M
Non-operating items
Interest & Investment Income (Quarter)	0.20M	0.40M	0.30M	0.30M	0.40M	1.50M	2.90M	4.80M	5.00M	8.80M	9.40M	6.20M	4.00M	4.60M	4.80M	4.10M	3.60M	4.70M	5.10M	5.10M
Other Non Operating Income (Quarter)	1.40M	1.10M	0.20M		0.20M	-49.30M	-2.20M		0.10M	3.80M	-0.90M			-0.70M	-0.30M	-0.20M	-0.20M	-0.20M	-0.40M	-0.20M
Non Operating Income (Quarter)	-0.30M	-1.80M	-2.10M	3.10M	-1.20M	-50.00M	26.30M	-12.90M	-4.00M	9.70M	-46.10M	-3.10M	-3.30M	-4.40M	-10.20M	-20.60M	-5.20M	-6.90M	-18.50M	-4.00M
Net income details
EBT (Quarter)	211.00M	181.10M	181.90M	187.80M	227.20M	136.20M	128.70M	157.90M	184.90M	187.00M	168.20M	127.40M	128.70M	164.50M	164.90M	110.50M	157.00M	171.90M	161.50M	180.10M
Tax Provisions (Quarter)	32.30M	12.00M	34.20M	21.20M	44.20M	20.40M	28.90M	23.60M	34.80M	29.40M	34.50M	16.40M	21.90M	32.40M	36.80M	24.10M	30.20M	34.00M	33.30M	44.70M
Profit After Tax (Quarter)	187.30M	175.60M	147.70M	173.80M	188.50M	120.60M	103.00M	140.00M	155.10M	161.30M	137.00M	115.30M	111.30M	136.00M	130.10M	89.80M	131.80M	140.00M	132.10M	138.80M
Income from Continuing Operations (Quarter)	178.70M	169.10M	147.70M	166.60M	183.00M	115.80M	99.80M	134.30M	150.10M	157.60M	133.70M	111.00M	106.80M	132.10M	128.10M	86.40M	126.80M	137.90M	128.20M	135.40M
Consolidated Net Income (Quarter)	178.70M	169.10M	147.70M	166.60M	183.00M	115.80M	99.80M	134.30M	150.10M	157.60M	133.70M	111.00M	106.80M	132.10M	128.10M	86.40M	126.80M	137.90M	128.20M	135.40M
Income towards Parent Company (Quarter)	178.70M	169.10M	147.70M	166.60M	183.00M	115.80M	99.80M	134.30M	150.10M	157.60M	133.70M	111.00M	106.80M	132.10M	128.10M	86.40M	126.80M	137.90M	128.20M	135.40M
Net Income towards Common Stockholders (Quarter)	178.70M	169.10M	147.70M	166.60M	183.00M	115.80M	99.80M	134.30M	150.10M	157.60M	133.70M	111.00M	106.80M	132.10M	128.10M	86.40M	126.80M	137.90M	128.20M	135.40M
Additional items
EPS (Basic) (Quarter)	2.41	2.28	1.99	2.24	2.46	1.56	1.34	1.80	2.02	2.12	1.80	1.51	1.46	1.81	1.75	1.19	1.76	1.91	1.77	1.88
EPS (Diluted) (Quarter)	2.36	2.23	1.94	2.19	2.41	1.53	1.32	1.77	1.99	2.09	1.78	1.49	1.45	1.80	1.74	1.18	1.75	1.90	1.76	1.87
Shares Outstanding (Quarter)	74.00M	74.10M	74.40M	74.40M	74.40M	74.40M	74.40M	74.50M	74.30M	74.30M	74.30M	73.50M	73.00M	72.80M	73.00M	72.50M	72.20M	72.20M	72.30M	72.00M
Shares Outstanding (Diluted) (Quarter)	75.70M	76.00M	76.30M	76.00M	75.80M	75.70M	75.80M	75.70M	75.40M	75.30M	75.30M	74.30M	73.70M	73.40M	73.70M	73.00M	72.50M	72.60M	72.70M	72.40M
Shares Outstanding (Entity) (Quarter)	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M	75.30M
EBITDA (Quarter)	211.30M	181.40M	184.00M	189.70M	228.40M	186.20M	129.70M	155.30M	182.50M	177.30M	160.90M	122.80M	126.20M	161.30M	159.60M	107.00M	153.70M	167.60M	156.60M	177.10M
Interest Expenses (Quarter)	3.10M	2.90M	2.60M	3.20M	3.10M	3.70M	7.10M	4.90M	5.00M	4.50M	4.70M	5.30M	15.00M	0.70M	19.40M	6.10M	113.50M	0.20M	5.90M	15.00M
Tax Rate (Quarter)	15.31%	6.63%	18.80%	11.29%	19.45%	14.98%	22.46%	14.95%	18.82%	15.72%	20.51%	12.87%	17.02%	19.70%	22.32%	21.81%	19.24%	19.78%	20.62%	24.82%

Research Tools

Developers

West Pharmaceutical Services Income Statement (2009-2026) | WST

Research Tools

Developers

West Pharmaceutical Services Income Statement (2009-2026) | WST

Create an account

Sign In

Reset Password